DMXAA

CAS No. 117570-53-3

DMXAA( ASA-404 | Vadimezan )

Catalog No. M10596 CAS No. 117570-53-3

A vascular disrupting agent (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 uM; activates STING dependent innate immune pathways.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 43 In Stock
5MG 73 In Stock
10MG 99 In Stock
25MG 215 In Stock
50MG 389 In Stock
100MG 428 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    DMXAA
  • Note
    Research use only, not for human use.
  • Brief Description
    A vascular disrupting agent (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 uM; activates STING dependent innate immune pathways.
  • Description
    A vascular disrupting agent (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 uM; activates STING dependent innate immune pathways.(In Vitro):Vadimezan (DMXAA), the vascular disrupting agent, is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan (DMXAA) has no detrimental effect on 344SQ-ELuc cell viability. It is found that Vadimezan-mediated up regulation of the NF-κB pathway as shown by increased p65 phosphorylation in M2 macrophages. Results demonstrate that Vadimezan (DMXAA)-treated cells are protected from VSV-induced cytotoxicity at all MOIs in contrast to medium-pretreated macrophages. Vadimezan (DMXAA) effectively inhibits growth of both strains of influenza, demonstrating the potential of Vadimezan for treatment of drug-resistant strains of human influenza. (In Vivo):344SQ-ELuc NSCLC subcutaneous tumors respond dramatically to Vadimezan (DMXAA), with a marked decrease in bioluminescence (BLI) signals post-drug injection. Vadimezan (DMXAA) treatment of 344SQ-ELuc metastases yields no decrease in photon emission rates, with the tumors remaining histologically similar to controls after this treatment. As with the large subcutaneous tumors, Vadimezan (DMXAA) administration to mice with small subcutaneous tumors still leads to ~2-log decreases in photon emission at both 6 and 24 hours. In vivo, Vadimezan (DMXAA) is a more potent inducer of IFN-β mRNA and a relatively poor inducer of TNF-α mRNA. Vadimezan (DMXAA) administration leads to significantly less weight loss in influenza-infected mice.
  • In Vitro
    Vadimezan (DMXAA), the vascular disrupting agent, is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan (DMXAA) has no detrimental effect on 344SQ-ELuc cell viability. It is found that Vadimezan-mediated up regulation of the NF-κB pathway as shown by increased p65 phosphorylation in M2 macrophages. Results demonstrate that Vadimezan (DMXAA)-treated cells are protected from VSV-induced cytotoxicity at all MOIs in contrast to medium-pretreated macrophages. Vadimezan (DMXAA) effectively inhibits growth of both strains of influenza, demonstrating the potential of Vadimezan for treatment of drug-resistant strains of human influenza.
  • In Vivo
    344SQ-ELuc NSCLC subcutaneous tumors respond dramatically to Vadimezan (DMXAA), with a marked decrease in bioluminescence (BLI) signals post-drug injection. Vadimezan (DMXAA) treatment of 344SQ-ELuc metastases yields no decrease in photon emission rates, with the tumors remaining histologically similar to controls after this treatment. As with the large subcutaneous tumors, Vadimezan (DMXAA) administration to mice with small subcutaneous tumors still leads to ~2-log decreases in photon emission at both 6 and 24 hours. In vivo, Vadimezan (DMXAA) is a more potent inducer of IFN-β mRNA and a relatively poor inducer of TNF-α mRNA. Vadimezan (DMXAA) administration leads to significantly less weight loss in influenza-infected mice.
  • Synonyms
    ASA-404 | Vadimezan
  • Pathway
    Autophagy
  • Target
    Autophagy
  • Recptor
    DT-diaphorase
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    117570-53-3
  • Formula Weight
    282.2906
  • Molecular Formula
    C17H14O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 6.5 mg/mL
  • SMILES
    O=C(O)CC1=CC=CC(C2=O)=C1OC3=C2C=CC(C)=C3C
  • Chemical Name
    9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Phillips RM. Biochem Pharmacol. 1999 Jul 15;58(2):303-10. 2. Prantner D, et al. J Biol Chem. 2012 Nov 16;287(47):39776-88. 3. Shirey KA, et al. J Leukoc Biol. 2011 Mar;89(3):351-7.
molnova catalog
related products
  • ATG7-IN-1

    ATG7-IN-1 is a selective ATG7 inhibitor with an IC50 of 62 nM.

  • AUTEN-67

    A small molecule autophagy enhancer that specificly inhibits myotubularin-related phosphatase MTMR14; at concentrations of 2, 10, and 100 uM, AUTEN-67 inhibits MTMR14 by nearly 3%, 25%, and 70%, respectively.

  • HADA Hydrochloride

    HADA Hydrochloride (HCC-Amino-D-alanine hydrochloride) is a blue (λem~450 nm) fluorescent D-amino acid (FDAA).